FDA Review Standards “Inconsistent” For New Drugs, Generics, PhRMA Says
This article was originally published in The Tan Sheet
Executive Summary
The lack of an integrated review staff for new drugs and generics has led to "inconsistent" review standards between new drug divisions and the Office of Generic Drugs, the Pharmaceutical Research & Manufacturers of America says in a "white paper" submitted to FDA
You may also be interested in...
GPhA Objection To Generic Drug Rule Could Backfire, FDA Counsel Troy Warns
The generic drug industry should carefully consider any attempt to derail FDA's regulatory approach to Hatch/Waxman reform, agency Chief Counsel Daniel Troy told the Generic Pharmaceutical Association
GPhA Objection To Generic Drug Rule Could Backfire, FDA Counsel Troy Warns
The generic drug industry should carefully consider any attempt to derail FDA's regulatory approach to Hatch/Waxman reform, agency Chief Counsel Daniel Troy told the Generic Pharmaceutical Association
GPhA Objection To Generic Drug Rule Could Backfire, FDA Counsel Troy Warns
The generic drug industry should carefully consider any attempt to derail FDA's regulatory approach to Hatch/Waxman reform, agency Chief Counsel Daniel Troy told the Generic Pharmaceutical Association